NCT02156999招募中4 期
Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Changes of bone mineral density
研究概览
简要总结
To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Osteoporosis
排除标准
- •Kidney, parathyroid, congenital bone metabolic disease
结局指标
主要结局
Changes of bone mineral density
时间窗: every 4-6 months
To examine the changes of bone mineral density for the purpose of the effectiveness of the drug
次要结局
- Improvement of bone turnover markers(Every 3-6 months)
研究者
Yukio Nakamura
Assistant professor
Shinshu University
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Effect on bone turnover and Bone Mineral Density (BMD) of low dose oral silicon as an adjunct to calcium/vitamin D3 in a randomised, placebo-controlled trialISRCTN57103074Bio Minerals N.V. (Belgium)184
进行中（未招募）
1 期
A Study to investigate Bone turnover Markers in patients planned to receive tofacitinibMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2018-003162-13-ITAZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA30
已完成
不适用
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of InterventionGrowth and DevelopmentNCT03155269GlaxoSmithKline114
进行中（未招募）
1 期
Bone turnover markers as predictors of treatment break outcomeMedDRA version: 19.0 Level: LLT Classification code 10031289 Term: Osteoporosis, unspecified System Organ Class: 100000004859OsteoporosisEUCTR2016-003110-27-DKBente Lomholt Langdahl, Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital140
招募中
不适用
Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort studytreatment-naive prostate cancer with bone metastasisJPRN-UMIN000018268Department of Renal and Urologic Surgery, Asahikawa Medical University50